Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD465 for Driving Safety in Adults with ADHD
NCT00458445Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Apr 2007
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Takeda. Primary endpoint: Simulated Driver Safety Score at Week 7. Planned start Apr 2007; status: withdrawn.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00458445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458445.